RONKONKOMA, N.Y., June 15, 2012—ReCor Medical, an emerging medical device company, reported today six-month follow-up data on eight patients who have been treated via renal denervation for their resistant hypertension with the Company’s PARADISE® System—the only system for renal denervation that is based on ultrasound, not radiofrequency, energy.

At six months follow-up, the PARADISE data showed that office systolic blood pressure was reduced by an average of 33 mm Hg in 8 patients. Of note: there were also significant and sustained blood pressure reductions in home and ambulatory measurements at six months. The scientific literature demonstrates that only a 5 mm Hg reduction in BP results in a 14% decrease in stroke, a 9% decrease in heart disease, and a 7% decrease in mortality.

The PARADISE ultrasound catheter was designed with the aim to allow complete circumferential denervation more consistently and efficiently than the standard of care radiofrequency ablation catheter. The procedure with the PARADISE system only requires 30 seconds of energy delivery per treatment location, thereby dramatically reducing the overall procedure time.

ReCor also announced that it has published a collection of video interviews conducted during ‘EuroPCR 2012’ with key opinion leaders (KOLs) on the topic of RENAL DENERVATION to treat resistant hypertension. (Click link above to see these videos.)

About ReCor Medical, Inc.

Founded in 2009, ReCor is a private venture-backed, early-stage company developing novel therapeutic ultrasound catheter technology. ReCor is backed by European and U.S. investors including Sofinnova Partners, one of the largest life science investors in Europe. The Company’s PARADISE™ technology for renal denervation is CE-marked. For more information about ReCor Medical, please visit the Company’s website at www.recormedical.com.